Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
EQRx, Inc. was a pharmaceutical company founded in 2019 with the ambitious mission to develop and deliver innovative, patent-protected medicines at radically lower prices. The company aimed to re-engineer the drug development and commercialization process to improve global access to important therapies. EQRx focused on creating a pipeline of new chemical entities and biologic drug candidates in high-cost areas like oncology and immunology. In November 2023, EQRx was acquired by Revolution Medicines.
Served as the central hub for strategic decision-making, research program management, business development, and administrative operations for EQRx's mission to develop and deliver affordable medicines.
Situated within Kendall Square, a dense cluster of biotech and pharmaceutical companies, offering a modern work environment. Facilities would have been aligned with life science R&D and corporate needs, though specific unique architectural details were not widely publicized.
EQRx fostered a mission-driven and innovative work culture, attracting individuals passionate about making medicines more affordable. The environment was likely fast-paced, collaborative, and focused on challenging traditional pharmaceutical industry models.
The Cambridge location provided EQRx with access to world-class scientific talent, leading research institutions, and a vibrant ecosystem of collaborators, investors, and service providers crucial for its drug development efforts.
Prior to its acquisition, EQRx aimed for a significant global presence, focusing on making its medicines accessible in major markets worldwide. This involved planning for international regulatory submissions, establishing strategic partnerships, and building out commercial capabilities beyond the US, with an initial focus on regions like Europe.
50 Hampshire Street
Cambridge
MA
USA
Address: Operations were managed through EQRx UK Ltd.; specific public street address for a large office is not widely publicized.
To establish a foothold in Europe, navigate UK and European healthcare systems, and support the company's mission of providing affordable medicines internationally.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, EQRx' leadership includes:
EQRx has been backed by several prominent investors over the years, including:
The 12 months leading up to and including EQRx's acquisition by Revolution Medicines (completed Nov 2023) saw significant executive changes. These were largely driven by strategic restructuring, including major layoffs in May 2023, and culminated in the dissolution of EQRx's independent leadership team upon acquisition.
Discover the tools EQRx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Revolution Medicines and cessation of independent operations, EQRx, Inc. likely utilized standard corporate email formats. These formats are now historical, and email addresses associated with the @eqrx.com domain are no longer active.
Common formats likely included [first_initial][last]@eqrx.com (e.g., jdoe@eqrx.com) or [first].[last]@eqrx.com (e.g., jane.doe@eqrx.com).
Format
jdoe@eqrx.com
Example
0%
Success rate
Revolution Medicines • November 10, 2023
Revolution Medicines announced the successful completion of its all-stock acquisition of EQRx. The transaction aimed to enhance Revolution Medicines' capabilities in developing and commercializing novel cancer therapies....more
GlobeNewswire • August 1, 2023
Revolution Medicines and EQRx announced they entered into a definitive agreement for Revolution Medicines to acquire EQRx in an all-stock transaction, positioning Revolution Medicines to build a fully integrated oncology company....more
Fierce Biotech • May 9, 2023
EQRx announced a significant restructuring, including laying off 170 employees (54% of its workforce) and discontinuing two cancer drug candidates. This marked a strategic shift away from its initial broad focus on radically lower drug prices towards a more conventional R&D model prior to its acquisition....more
Fierce Biotech (referencing launch) • January 12, 2020
EQRx officially launched with $200 million in Series A financing, co-founded by Alexis Borisy. The company's stated goal was to create affordable versions of patent-protected innovative medicines....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including EQRx, are just a search away.